{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:38:34Z","timestamp":1759797514435,"version":"build-2065373602"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Key Research and Development Program of China","award":["2022YFC2703104"],"award-info":[{"award-number":["2022YFC2703104"]}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-PUMCH-D-002"],"award-info":[{"award-number":["2022-PUMCH-D-002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"DOI":"10.1186\/s12883-025-04441-9","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:42:59Z","timestamp":1759754579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disease characteristics and treatment status of genetically confirmed spinal muscular atrophy patients: a cross-sectional survey in China"],"prefix":"10.1186","volume":"25","author":[{"given":"Dingding","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengxia","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Ling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xunzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"4441_CR1","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","volume":"8","author":"E Mercuri","year":"2022","unstructured":"Mercuri E, Sumner CJ, Muntoni F, Darras BT, Finkel RS. Spinal muscular atrophy. Nat Rev Dis Primers. 2022;8:52.","journal-title":"Nat Rev Dis Primers"},{"key":"4441_CR2","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.nmd.2017.11.005","volume":"28","author":"E Mercuri","year":"2018","unstructured":"Mercuri E, Finkel RS, Muntoni F, Wirth B, Montes J, Main M, et al. Diagnosis and management of spinal muscular atrophy: part 1: recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul Disord. 2018;28:103\u201315.","journal-title":"Neuromuscul Disord"},{"key":"4441_CR3","first-page":"231","volume":"2","author":"Y Dai","year":"2023","unstructured":"Dai Y, Cui LY, Zhang GY, Luo JM, Xiao Y, Cui XL, et al. Clinical practice guideline for adolescent & adult patients with spinal muscular atrophy. J Rare Dis. 2023;2:231\u201355.","journal-title":"J Rare Dis"},{"key":"4441_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.01255","volume":"10","author":"Y Lin","year":"2019","unstructured":"Lin Y, Lin CH, Yin X, Zhu L, Yang J, Shen Y, et al. Newborn screening for spinal muscular atrophy in China using DNA mass spectrometry. Front Genet. 2019;10:1255.","journal-title":"Front Genet"},{"key":"4441_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000018975","volume":"99","author":"C Li","year":"2020","unstructured":"Li C, Geng Y, Zhu X, Zhang L, Hong Z, Guo X, et al. The prevalence of spinal muscular atrophy carrier in China: evidences from epidemiological surveys. Medicine. 2020;99:e18975.","journal-title":"Medicine"},{"key":"4441_CR6","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00018-022-04522-9","volume":"79","author":"NT Detering","year":"2022","unstructured":"Detering NT, Sch\u00fcning T, Hensel N, Claus P. The phospho-landscape of the survival of motoneuron protein (SMN) protein: relevance for spinal muscular atrophy (SMA). Cell Mol Life Sci. 2022;79:497.","journal-title":"Cell Mol Life Sci"},{"key":"4441_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1474-4422(12)70061-3","volume":"11","author":"E Mercuri","year":"2012","unstructured":"Mercuri E, Bertini E, Iannaccone ST. Childhood spinal muscular atrophy: controversies and challenges. Lancet Neurol. 2012;11:443\u201352.","journal-title":"Lancet Neurol"},{"key":"4441_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.928581","volume":"9","author":"NN Singh","year":"2022","unstructured":"Singh NN, O\u2019Leary CA, Eich T, Moss WN, Singh RN. Structural context of a critical exon of spinal muscular atrophy gene. Front Mol Biosci. 2022;9:928581.","journal-title":"Front Mol Biosci"},{"key":"4441_CR9","doi-asserted-by":"crossref","unstructured":"Aslesh T, Yokota T, Restoring SMN, Expression. An overview of the therapeutic developments for the treatment of spinal muscular atrophy. Cells. 2022;11.","DOI":"10.3390\/cells11030417"},{"key":"4441_CR10","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.2147\/DDDT.S214174","volume":"16","author":"HT Hjartarson","year":"2022","unstructured":"Hjartarson HT, Nathorst-B\u00f6\u00f6s K, Sejersen T. Disease modifying therapies for the management of children with spinal muscular atrophy (5q SMA): an update on the emerging evidence. Drug Des Devel Ther. 2022;16:1865\u201383.","journal-title":"Drug Des Devel Ther"},{"key":"4441_CR11","first-page":"473","volume":"77","author":"SM Hoy","year":"2017","unstructured":"Hoy SM, Nusinersen. First Global Approval Drugs. 2017;77:473\u20139.","journal-title":"First Global Approval Drugs"},{"key":"4441_CR12","first-page":"1853","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Risdiplam. First Approval Drugs. 2020;80:1853\u20138.","journal-title":"First Approval Drugs"},{"key":"4441_CR13","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/ana.26299","volume":"91","author":"CJJ Yeo","year":"2022","unstructured":"Yeo CJJ, Simmons Z, De Vivo DC, Darras BT. Ethical perspectives on treatment options with spinal muscular atrophy patients. Ann Neurol. 2022;91:305\u201316.","journal-title":"Ann Neurol"},{"key":"4441_CR14","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1038\/s41591-022-01867-3","volume":"28","author":"KA Strauss","year":"2022","unstructured":"Strauss KA, Farrar MA, Muntoni F, Saito K, Mendell JR, Servais L, et al. Onasemnogene abeparvovec for presymptomatic infants with three copies of SMN2 at risk for spinal muscular atrophy: the phase III spr1nt trial. Nat Med. 2022;28:1390\u20137.","journal-title":"Nat Med"},{"key":"4441_CR15","doi-asserted-by":"publisher","first-page":"425","DOI":"10.3233\/JND-230122","volume":"11","author":"L Servais","year":"2024","unstructured":"Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F, et al. Real-world outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. J Neuromuscul Dis. 2024;11:425\u201342.","journal-title":"J Neuromuscul Dis"},{"key":"4441_CR16","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40273-021-01118-2","volume":"40","author":"SH Lo","year":"2022","unstructured":"Lo SH, Lawrence C, Mart\u00ed Y, Caf\u00e9 A, Lloyd AJ. Patient and caregiver treatment preferences in type 2 and non-ambulatory type 3 spinal muscular atrophy: a discrete choice experiment survey in five European countries. Pharmacoeconomics. 2022;40:103\u201315.","journal-title":"Pharmacoeconomics"},{"key":"4441_CR17","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/acn3.51281","volume":"8","author":"M Annoussamy","year":"2021","unstructured":"Annoussamy M, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Natural history of type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2021;8:359\u201373.","journal-title":"Ann Clin Transl Neurol"},{"key":"4441_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1186\/s13023-022-02455-x","volume":"17","author":"C Cances","year":"2022","unstructured":"Cances C, Vlodavets D, Comi GP, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Saito K, et al. Natural history of type 1 spinal muscular atrophy: a retrospective, global, multicenter study. Orphanet J Rare Dis. 2022;17:300.","journal-title":"Orphanet J Rare Dis"},{"key":"4441_CR19","first-page":"3130","volume":"100","author":"Beijing Medical Genetics Society BAoRDD, Treatment and Security","year":"2020","unstructured":"Beijing Medical Genetics Society BAoRDD, Treatment and Security. Consensus statement on the genetic diagnosis of spinal muscular atrophy. Natl Med J China. 2020;100:3130\u201340.","journal-title":"Natl Med J China"},{"key":"4441_CR20","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1111\/dmcn.15135","volume":"64","author":"KA Carey","year":"2022","unstructured":"Carey KA, Farrar MA, Kasparian NA, Street DJ, De Abreu Lourenco R. Family, healthcare professional, and societal preferences for the treatment of infantile spinal muscular atrophy: a discrete choice experiment. Dev Med Child Neurol. 2022;64:753\u201361.","journal-title":"Dev Med Child Neurol"},{"key":"4441_CR21","doi-asserted-by":"publisher","DOI":"10.3233\/JND-240007","author":"HW van Bruggen","year":"2024","unstructured":"van Bruggen HW, Wijngaarde CA, Asselman F, Stam M, Creugers NHJ, Wadman RI, et al. Natural history of mandibular function in spinal muscular atrophy types 2 and 3. J Neuromuscul Dis. 2024. https:\/\/doi.org\/10.3233\/JND-240007.","journal-title":"J Neuromuscul Dis"},{"key":"4441_CR22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.tins.2020.11.009","volume":"44","author":"B Wirth","year":"2021","unstructured":"Wirth B. Spinal muscular atrophy: in the challenge lies a solution. Trends Neurosci. 2021;44:306\u201322.","journal-title":"Trends Neurosci"},{"key":"4441_CR23","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1212\/WNL.0000000000007836","volume":"93","author":"DC Schorling","year":"2019","unstructured":"Schorling DC, Becker J, Pechmann A, Langer T, Wirth B, Kirschner J. Discrepancy in redetermination of SMN2 copy numbers in children with SMA. Neurology. 2019;93:267\u20139.","journal-title":"Neurology"},{"key":"4441_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.1038012","volume":"13","author":"C Hu","year":"2022","unstructured":"Hu C, Li X, Shi Y, Zhu X, Zhao L, Li W, et al. Comprehensive profile and natural history of pediatric patients with spinal muscular atrophy: a large retrospective study from China. Front Neurol. 2022;13:1038012.","journal-title":"Front Neurol"},{"key":"4441_CR25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1177\/0883073811420152","volume":"27","author":"X Ge","year":"2012","unstructured":"Ge X, Bai J, Lu Y, Qu Y, Song F. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J Child Neurol. 2012;27:471\u20137.","journal-title":"J Child Neurol"},{"key":"4441_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1357476","volume":"15","author":"BB Zhou","year":"2024","unstructured":"Zhou BB, Chen X, Zhang C, Wang YP, Ma PP, Hao SJ, et al. Analysis of spinal muscular atrophy carrier screening results in 32,416 pregnant women and 7,231 prepregnant women. Front Neurol. 2024;15:1357476.","journal-title":"Front Neurol"},{"key":"4441_CR27","doi-asserted-by":"publisher","first-page":"7341","DOI":"10.2147\/IJGM.S369021","volume":"15","author":"L Ramos-Platt","year":"2022","unstructured":"Ramos-Platt L, Elman L, Shieh PB. Experience and perspectives in the US on the evolving treatment landscape in spinal muscular atrophy. Int J Gen Med. 2022;15:7341\u201353.","journal-title":"Int J Gen Med"},{"key":"4441_CR28","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1111\/ene.14902","volume":"28","author":"T Meyer","year":"2021","unstructured":"Meyer T, Maier A, Uzelac Z, Hagenacker T, Gunther R, Schreiber-Katz O, et al. Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving Nusinersen. Eur J Neurol. 2021;28:2582\u201395.","journal-title":"Eur J Neurol"},{"key":"4441_CR29","doi-asserted-by":"publisher","first-page":"175628642199890","DOI":"10.1177\/1756286421998902","volume":"14","author":"A Osmanovic","year":"2021","unstructured":"Osmanovic A, Ranxha G, Kumpe M, Wurster CD, Stolte B, Cordts I, et al. Treatment satisfaction in 5q-spinal muscular atrophy under Nusinersen therapy. Ther Adv Neurol Disord. 2021;14:1756286421998902.","journal-title":"Ther Adv Neurol Disord"},{"key":"4441_CR30","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/mus.28015","volume":"69","author":"JC Powell","year":"2024","unstructured":"Powell JC, Meiling JB, Cartwright MS. A case series evaluating patient perceptions after switching from Nusinersen to Risdiplam for spinal muscular atrophy. Muscle Nerve. 2024;69:179\u201384.","journal-title":"Muscle Nerve"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-025-04441-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-025-04441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T12:43:01Z","timestamp":1759754581000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-025-04441-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4441"],"URL":"https:\/\/doi.org\/10.1186\/s12883-025-04441-9","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,6]]},"assertion":[{"value":"16 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in compliance with the Helsinki Declaration and received ethical approval from the Ethics Committee of Peking Union Medical College Hospital. All participants provided informed consent prior to participation. For participants under 16 years of age, consent to participate was obtained from their parents or legal guardians.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"411"}}